Navco Pharmaceuticals Inc.
NAV.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 60.12% | 37.75% | 20.63% | 113.84% | -907.25% |
| Total Depreciation and Amortization | -39.33% | 42.64% | 65.95% | 95.57% | 90.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -46.93% | 23.98% | 23.75% | -150.09% | 9,669.52% |
| Change in Net Operating Assets | 131.12% | 116.87% | 133.85% | 126.13% | -381.07% |
| Cash from Operations | 97.25% | 94.70% | 85.91% | 47.68% | -3,619.76% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | 648.00% | -- |
| Total Debt Repaid | 72.71% | 60.76% | 72.80% | 76.02% | 13.89% |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -63.83% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -1,176.19% | -- |
| Cash from Financing | -89.18% | -98.68% | -98.72% | -101.49% | -67.53% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 99.81% | -246.82% | -201.39% | -199.66% | -199.19% |